Based on a Cardiac Safety Research Consortium Think Tank held in October 2017 on “Detection, Assessment, and Risk Mitigation of Cardiac Safety Signals in Oncology Drug Development, this publication discusses emerging cardio-oncology nuances and the latest regulatory thinking on ways to manage risks.
Error - something went wrong!
Placebo Response Reduction
WCG has developed and validated the industry-leading Placebo Response Reduction training program.
Request a Genetics in Clinical Trials training sessionWhat You'll Learn
Most Recent Flipbooks
More Than Good Intentions: DE&I Requires a Program- Level, Strategic Framework
Run Your Site Like a Business - A Framework for Success
Your Questions Answered - Coverage Analysis and Billing Compliance Town Hall
Investigator Compensation - Understanding the Basics and Avoiding Pitfalls
Reimagining the Clinical Research Model
Ideal vs. Reality Budgeting - Create & Negotiate the Best Clinical Trial Budget for Your Site
Why Web-Based Study Training is the New Norm for Clinical Trials
Better Budgets and Negotiations - Tips and Tricks for Research Sites
National and Local Coverage Determinations Every Coverage Analyst Should Know
No Longer an Afterthought - A Call for Greater Diversity and Inclusion in Clinical Trials
Q&A - Negotiating Clinical Trial Agreements for Sites
Q&A - Frequently Asked Research Billing Compliance Questions
Relieving the Safety Reporting Burden on Sites: 4 Takeaways
The BNSS Scale In Translation: A Review of Psychometric Properties and Beyond
Translational Research Key to Meeting Real-World Needs During Pandemic
Using Predictable and Efficient Data to Take the Risk Out of Site Selection
Article - Coverage Analysis for Non-COVID Trials During the Pandemic
What is a Coverage Analysis and Why are They Important for Research Programs?
Making Coverage Analysis Determinations for Outside-the-Box Situations
Design and Conduct of Confirmatory Chronic Pain Clinical Trials